-
Innovation is becoming the general trend of the development of the domestic equipment industry!
Time of Update: 2023-01-01
For example, on November 14, the State Medical Products Administration approved the registration application for artificial bone repair materials submitted by Wuhan Asia Biomaterials Co.
For example, on November 14, the State Medical Products Administration approved the registration application for artificial bone repair materials submitted by Wuhan Asia Biomaterials Co.
-
Local pharmaceutical companies are actively expanding the European biopharmaceutical market
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];With the improvement of the R&D strength of domestic innovative pharmaceutical enterprises and the intensification of the "involution" of the domestic pharmaceutical market, going global will become one of the important layouts for the sustainable development of local pharmaceutical companies.
-
The epigenetics track is on the rise, and Merck, BMS, etc. are increasing their layout
Time of Update: 2023-01-01
Therefore, epigenetic enzymes have gradually become an important target for drug discovery and development, and at the same time, this field is constantly attracting the attention and investment of large pharmaceutical companies.
-
The new round of medical insurance negotiations is expected to have limited room for innovative drugs, and the industry recommends paying attention to sector opportunities
Time of Update: 2023-01-01
The countdown to the 2022 health care negotiations is expected to officially begin in early December. In this round of medical insurance negotiations, innovative drugs such as BeiGene's CD3/CD19 dual
-
Good news has spread in the injection industry, and a number of new drugs have been approved for clinical trials
Time of Update: 2023-01-01
, a wholly-owned subsidiary of the company, has recently received the "Drug Registration Certificate" for ambroxol hydrochloride injection approved and issued by the State Medical Products Administration.
-
National Health Commission: Continue to increase the supervision of nucleic acid testing institutions
Time of Update: 2023-01-01
We have noticed that some places try to carry out nucleic acid self-collection in different forms, but special attention should be paid to the standardization, effectiveness and safety of self-collected nucleic acid, and a sound implementation plan should be formulated, and at the same time, it is necessary to do a good job in organizing implementation and strengthening technical guidance.
-
Daan Gene took the initiative to apply for a price reduction, or open a price war in the molecular diagnostic industry!
Time of Update: 2023-01-01
Recently, the centralized procurement platform for drugs and medical consumables in Gansu Province issued a notice that after receiving an application from an enterprise, 97 of the 53 registration certificates of the external diagnostic reagent products took the initiative to apply for a price reduction (Daan Gene), of which 12 new declaration registration certificates were reviewed and passed in accordance with the "green channel".
-
Good management practices for drug sales: quality management of drug retail distribution
Time of Update: 2023-01-01
Article 6: Pharmaceutical retail enterprises shall, in accordance with the relevant provisions of the Norms, formulate a quality management system for drug distribution, including personnel management, job responsibilities, facilities and equipment, operating procedures, records and vouchers, emergency management, and other such content, and periodically review and promptly revise them.
-
HER2 exon 20 inserted mutation lung cancer (NSCLC) innovative drug! Pan-HER tyrosine kinase inhibitor poziotinib has suffered a major regulatory setback, and Luye Pharmaceutical has the rights in China!
Time of Update: 2023-01-01
The NDA seeks approval for poziotinib: a novel, oral, irreversible EGFR family receptor-blocking pan-HER inhibitor for the treatment of previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying HER2 exon 20 insertion mutations (Ex20ins).
-
Sanqi price reduction, Zhongheng Group's performance is expected to recover!
Time of Update: 2023-01-01
On October 29, Guangxi Wuzhou Zhongheng Group Co. , Ltd. (Zhongheng Group, 600252) released the third quarter report of 2022, showing that the operating income in the first three quarters of 2022 was
-
More than 30 pharmaceutical companies have seen significant shareholder reductions, and these companies have the largest amount of shareholding
Time of Update: 2023-01-01
According to statistics, in November, the directors, supervisors and related persons of listed companies in Shanghai and Shenzhen reduced their holdings by a total of about 5.
-
On December 5, the pharmaceutical industry received a net purchase of nearly 1.2 billion yuan, and a number of shares received a net purchase of more than 100 million yuan
Time of Update: 2023-01-01
According to the Flush Data Center, Xinhua Pharmaceutical received financing to buy 155 million yuan on December 5, accounting for 18.
On December 5, Tongce Medical received financing to buy 103 million yuan, accounting for 15.
-
Over 1000 bits! What signal does the departure of executives of listed pharmaceutical companies send?
Time of Update: 2023-01-01
(Image source: Pharma Network) Flush data shows that as of November 17, more than 1,400 executives in the A-share biomedical industry left the year, involving 357 enterprises.
-
Under the "hoarding tide", ibuprofen production enterprises have attracted the attention of institutions and investors
Time of Update: 2023-01-01
Rundu shares Rundu replied to investors on November 15 that the company's product ibuprofen sustained-release capsules are suitable for relieving mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, and dysmenorrhea.
-
Ningbo Municipal Supervision Bureau: Fine up to 5 million yuan for manipulating the market price of medical supplies
Time of Update: 2023-01-01
Ningbo Market Supervision WeChat public account news, Ningbo Market Supervision Administration issued the "Reminder on the Price Behavior of Medical Drugs and Supplies" on the 6th. It is proposed that
-
The improvement of the quality of Chinese medicine pieces still needs to be accelerated, and the upstream pharmaceutical machine industry may be affected
Time of Update: 2023-01-01
In order to strengthen drug quality supervision and ensure the safety of public drug use, local drug regulatory departments are conducting frequent supervision and sampling inspections on the quality
-
National Action Plan to Curb Microbial Resistance (2022-2025)
Time of Update: 2023-01-01
All provinces, autonomous regions, municipalities directly under the Central Government, and the Xinjiang Production and Construction Corps Health Commission, Education Department (Education Commissi
-
Listed companies continue to increase share buybacks, and pharmaceutical companies are also setting off a "buyback tide"
Time of Update: 2023-01-01
78 yuan / share, and the total amount of funds paid was 150 million yuan (excluding stamp duty, transaction commissions and other transaction 。 On December 1, CanSino announced that as of November 30, the company had repurchased a total of 670,100 A shares in a centralized bidding transaction, accounting for 0.
-
Pharmaceutical companies have set off a "wave of cooperation", involving new drug research and development, commercialization...
Time of Update: 2023-01-01
Becton Medical has joined forces with NanoString On December 1, medical technology company Becton Medical and NanoString jointly announced that they will start a strategic cooperation in the field of single-cell spatial multiomics, combining the advantages of both parties to provide one-stop technical tools and services for domestic basic scientific research, clinical research and biomedical research and development.
-
Over $2 billion! Regeneron collaborates with CytomX to develop a new generation of dual antibodies
Time of Update: 2023-01-01
On November 17, Regeneron and CytomX Therapeutics announced a collaboration and license agreement to develop conditionally activated experimental next-generation bispecific cancer therapies using CytomX's Probody therapeutic platform and Regeneron's Veloci-Bi bispecific antibody development platform.
